PHAXIAM Therapeutics S.A. - Asset Resilience Ratio

Latest as of June 2024: 3.74%

PHAXIAM Therapeutics S.A. (PHXM) has an Asset Resilience Ratio of 3.74% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore PHAXIAM Therapeutics S.A. balance sheet assets for the complete picture of this company's asset base.

Liquid Assets

€1.46 Million

≈ $1.71 Million USD Cash + Short-term Investments

Total Assets

€39.11 Million

≈ $45.72 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how PHAXIAM Therapeutics S.A.'s Asset Resilience Ratio has changed over time. See PHAXIAM Therapeutics S.A. net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down PHAXIAM Therapeutics S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PHAXIAM Therapeutics S.A. market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€1.46 Million	3.74%
Short-term Investments	€0.00	0%
Total Liquid Assets	€1.46 Million	3.74%

Asset Resilience Insights

Limited Liquidity: PHAXIAM Therapeutics S.A. maintains only 3.74% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PHAXIAM Therapeutics S.A. Industry Peers by Asset Resilience Ratio

Compare PHAXIAM Therapeutics S.A.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	82.25%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for PHAXIAM Therapeutics S.A. (2016–2023)

The table below shows the annual Asset Resilience Ratio data for PHAXIAM Therapeutics S.A..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	20.41%	€10.47 Million ≈ $12.25 Million	€51.31 Million ≈ $59.98 Million	-64.35pp
2022-12-31	84.77%	€38.83 Million ≈ $45.40 Million	€45.81 Million ≈ $53.56 Million	+33.58pp
2021-12-31	51.19%	€34.18 Million ≈ $39.96 Million	€66.77 Million ≈ $78.06 Million	-4.10pp
2020-12-31	55.29%	€44.45 Million ≈ $51.97 Million	€80.40 Million ≈ $94.00 Million	-6.45pp
2019-12-31	61.74%	€73.19 Million ≈ $85.56 Million	€118.55 Million ≈ $138.59 Million	-18.32pp
2018-12-31	80.06%	€134.37 Million ≈ $157.09 Million	€167.84 Million ≈ $196.22 Million	-3.66pp
2016-12-31	83.72%	€37.65 Million ≈ $44.01 Million	€44.97 Million ≈ $52.57 Million	--

pp = percentage points

About PHAXIAM Therapeutics S.A.

PA:PHXM France Biotechnology

Market Cap

$1.18 Million

€1.01 Million EUR

Market Cap Rank

#30407 Global

#571 in France

Share Price

€0.10

Change (1 day)

+0.00%

52-Week Range

€0.10 - €0.22

All Time High

€283.83